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Background In 2013, the European Food Safety Authority approved a health claim (ID 558) 
relating to lowered post-prandial glycaemic response when food manufacturers substitute a 
minimum of 30% of sucrose and/or glucose with fructose in foods and beverages. The 
presumed benefits of this health claim were based on studies showing lowered post-
prandial glycaemic response to test meals and drinks containing 100% fructose in 
comparison with sucrose and glucose. In short, no studies have been carried out to test 
partial fructose replacement and its presumed health outcomes. Fructose confers a lower 
glycaemic response relative to sucrose and glucose due to differences in metabolism but has 
also been implicated in the development of metabolic abnormalities such as hyperuricemia 
as well as other chronic diseases.  
Aim To assess whether partial replacement of sucrose with fructose in a carbonated 
beverage has significant effect on acute glucose, uric acid and blood pressure response. 
Methods In this randomised crossover trial, 12 normoglycaemic participants consumed 5 
carbonated beverages on five separate occasions sweetened with 50 gram blends of 
fructose and sucrose in varying proportions; 33% fructose and 67% sucrose (33F:67S), 50% 
fructose and 50% sucrose (50F:50S) and 67% fructose and 33% sucrose (67F:33S), and 100% 
sucrose which was tested twice as the reference. Blood pressure, plasma glucose and uric 
acid were measured at 0, 15, 30, 45, 60, 90 and 120 minutes, which were used to determine 
incremental and net area under the curve.  
Results There was a significant trend for glycaemic response to decrease as fructose 
increased in a dose-response manner (p<0.001). There were no statistically significant 
differences for glycaemic response between the sucrose reference treatment and 33F:67S. 
Uric acid was raised significantly (p<0.000) for all fructose-replacement beverages compared 
to sucrose. There were generally no significant differences in blood pressure between 
fructose-replacement beverages and sucrose, except for a significant reduction in systolic 




Conclusion There were no significant reductions in glycaemic response found when fructose 
replaces 33% of sucrose in a carbonated beverage; however this replacement substantially 
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In 2013, the European Food Safety Authority permitted a health claim (ID558) on foods and 
beverages  in which a minimum of 30% of sucrose or glucose was replaced with fructose 
(Agostoni C, 2011). The rationale for this claim is a reduction in post-prandial glycaemic 
(PPG) response. However, evidence for a glycaemic reduction was substantiated from 
studies in which the PPG response of 100% sucrose and glucose was compared with 100% 
fructose.  
Fructose, a monosaccharide, is present in some fruits and vegetables as “intrinsic fructose” 
and is also manufactured in crystallised form (Thornley et al., 2012). “Added fructose” 
comprises 50% of the disaccharide sucrose,  which is commonly found in manufactured food 
products such as carbonated beverages and confectionary (White, 2014). Fructose also 
comprises approximately 42-55% of high fructose corn syrup (HFCS) which is mainly 
consumed in North America (White, 2014). The metabolism of fructose differs from glucose; 
it is insulin-independent, primarily metabolised by the liver and is phosphorylated at a faster 
rate than glucose (Lieberman et al., 2013;Tappy et al., 2014).    
 Studies have consistently demonstrated that the acute glycaemic response of fructose is 
lower than that of glucose and sucrose in those with normal and compromised glucose 
metabolism (Akgun and Ertel, 1980;Bantle et al., 1983;Crapo et al., 1980;Foster-Powell et 
al., 2002;Gannon et al., 1986;Jenkins et al., 1981). This observation led to fructose being 
recommended as a sweetener for those with diabetes in the 1970’s (Tappy et al., 2014). 
However, this recommendation was discontinued by the American Diabetes Association 
after fructose was also shown to adversely affect plasma lipids  (ADA, 2008;Brunzell et al., 
2003;Livesey and Taylor, 2008).  
  The metabolism of fructose also produces uric acid (UA) (Emmerson, 1974). The rise in 
fructose intake through the increased consumption of sugar and high fructose corn syrup 
(HFCS) from the 1970’s to 2000’s (Thornley et al., 2012), speculation arose that  this 
increased fructose consumption was linked to the development of hyperuricemia and gout 
(Choi et al., 2005). Additionally, animal feeding trials that fed 60% of total energy as fructose 




consumption was associated with increased risk of hypertension in humans (Emmerson, 
1974;Feig, 2012;Martinez et al., 1994;Singh et al., 2008). Another feeding study indicated 
that fructose feeding at 25% excess energy (125-180g/d) were also predisposed to 
deposition of visceral adiposity, dyslipidemia and insulin sensitivity more than glucose 
(Stanhope et al., 2009). However, this dose is nearly triple the average fructose intake of the 
average New Zealander, questioning the generalisability of this finding to the NZ population.    
Epidemiological studies have linked increasing added fructose consumption with metabolic 
disorders such as obesity, diabetes, metabolic syndrome, reduce satiety, NAFLD, 
cardiovascular diseases (Bray, 2010;Chiu et al., 2014;DiNicolantonio et al., 2015;Silbernagel 
et al., 2011). This has led to claims of fructose even being labelled “toxic”, and calls have 
been made to impose a “sugar tax” on products containing added fructose (Lustig et al., 
2012). However, some researchers hold the position that evidence from hypercaloric 
feeding trials is of lower quality as fructose is administered at unrealistic intakes instead of 
“real world” intakes (Chiavaroli et al., 2014;Houston and Minich, 2015;Sievenpiper et al., 
2012). They also question whether it is appropriate to use findings from animal studies as a 
study rationale for human investigations, due to species differences in metabolic physiology 
(Chiavaroli et al., 2014).   
However, SSB’s provide an exposure for fructose and a number of studies have consistently 
shown that increasing SSB consumption is  linked with weight gain and obesity, and theorise 
that decreasing SSB consumption could contribute to the prevention of obesity-related 
diseases such as diabetes and cardiovascular disease (Hu, 2013;Malik et al., 2013). Indeed, 
in 2015, WHO strongly recommended that free sugar intake be reduced to 10% of total 
energy (WHO, 2015).   
With regard to EFSA health claim ID 558, the PPG response to partially-replaced sucrose or 
glucose with fructose has never been tested, so the practical implication of this health claim 
in the context of acute glycaemic response is still unclear. Also unclear is how additional 
fructose in beverages will affect the UA and BP response. Therefore, the primary aim of this 
study is to test the effect  of partial replacement of sucrose with fructose on glycaemic and  





 2 Literature Review 
 
2.1 Methodology of literature review 
 
This literature review focuses on discussing the effect of fructose on human glycaemic, 
uricaemic and BP response in comparison with sucrose.  
The following literature reviews aims to do the following: 
1. Provide an overview of fructose, commonly produced nutritive sweeteners, fructose 
metabolism and current fructose intake in NZ and international populations.  
2. Discuss the findings of research concerning the potential benefits and pathological 
risks of fructose consumption on glycaemic, UA and BP response in comparison with 
sucrose.  
3. Provide a brief overview on the effect of fructose consumption in relation to chronic 
disease and metabolic disorders.  
Literature was obtained from PubMed, Google Scholar and the reference lists of published 
articles using the key words “fructose”, “glycaemic response”, “glycaemic control”, “uric 
acid”, “hyperuricaemia”, “blood pressure”, “hypertension”, “metabolic effects”.   
2.2 Fructose 
 
Fructose is a naturally occurring ketohexose monosaccharide molecule (Lieberman et al., 
2013). Fructose is generally believed to be sweeter than sucrose (Fontvieille et al., 1989). 
Fructose is naturally present in fruits, honey and some root vegetables (Thornley et al., 
2012). Fructose can be extracted, crystallised and added to food; it is present in the food 
supply as sucrose (fructose bound to glucose), and as HFCS (White, 2014). HFCS is a corn 
derived sweetener which is mainly used in North America; 79% of all HFCS produced in the 
USA is used to sweeten beverages (White, 2014). HFCS is commercially available in varying 
proportions of fructose; the most widely used forms being HFCS-55 and HFCS-42 (White, 




the USA(USDA, 2016). HFCS-42 is also used for producing cereal and baked goods, dairy 
products and confectionery (USDA, 2016). 
2.2.1 Fructose intakes 
 
In national surveys, fructose intakes may be reported as intrinsic fructose (naturally present 




  In the 2008-09 New Zealand Adults National Nutrition Survey, the median usual daily 
intake of total fructose in NZ was 49.1 grams for males and 39 grams for females (University 
of Otago, 2011).  In the USA, mean fructose intake reported was 54.7 grams, with 
adolescents aged 12-18 years old in the highest fructose consumption category consuming 
72.8 grams of fructose per day (Vos et al., 2008). The median fructose intake in the 
Figure 2.1 Molecular structures of sucrose and HFCS before and after digestion and 




Netherlands between 2007 and 2010 was 46 grams per day, comprising 9% of mean daily 
energy intake in the general population (Sluik et al., 2014).  
2.2.2 Fructose transport and hepatic metabolism 
 
Fructose is absorbed by the epithelial cells of the small intestine through the transporter 
GLUT5 where it is transported into the hepatic portal vein via the GLUT2, whereas glucose is 
transported from the intestine into the plasma through different transporters, SGLT1 and 
GLUT2 (Lieberman et al., 2013;Tappy et al., 2014). Fructose metabolism proceeds without 
the presence of insulin and is metabolised primarily by the liver (Tappy et al., 2014). The 
subsequent phosphorylation of fructose that produces fructose 1 phosphate is a step that 
occurs without rate limitation, as fructokinase has a high affinity for fructose (Lieberman et 
al., 2013;Tappy et al., 2014). The metabolism of isotopically labelled fructose has been 
found to produce (28-54%) glucose, (25%) lactate, glycogen, glycerol and (<1%) lipids (Sun 
and Empie, 2012). However, there may be considerable variability in the proportion of these 
metabolic products depending on factors such as the dose of fructose consumed, whether 
the body is at rest or exercising, whether glucose is consumed simultaneously with fructose 







2.3 Fructose and Glycaemia 
 
In the 1980’s, it was reported that fructose elicited a small glycaemic response relative to 
glucose (Akgun and Ertel, 1980;Gannon et al., 1986;Jenkins et al., 1981). Fructose is 
classified as an available carbohydrate, as it is capable of providing energy after digestion 
and absorption in the body (Weinmann, 1947). As previously described, between 28-54% of 
fructose may be converted to glucose. However, fructose is still mildly glycaemic relative to 
glucose, as a considerable amount of fructose is also directed towards replenishing liver 
glycogen and lactate production (Sun and Empie, 2012). 
The glycaemic response of fructose has been measured and quantified through glycaemic 
index testing (Foster-Powell et al., 2002). GI is expressed as a percentage of glycaemic 
response of a test food, measured as Area Under the Curve (AUC) relative to the glycaemic 
response elicited from a reference food, usually a glucose beverage or white bread (Venn 
and Green, 2007). The amount of available CHO in both test foods and reference foods must 




be equal (usually 50 grams) and testing is conducted on two separate occasions by the same 
individual under standardised GI testing protocol (Venn and Green, 2007). Studies that 
investigate the acute effects of fructose feeding with sucrose and glucose controls 
consistently observe reduced glycaemic response compared to glucose and sucrose controls 
(Bantle et al., 1983;Crapo et al., 1980;Lee and Wolever, 1998). Overall, the mean (SD) GI 
values of fructose and sucrose relative to glucose are 19 (2) and 68 (5) (Foster-Powell et al., 
2002). There is no research conducted to date that has investigated the acute glycaemic 
response to the partial substitution of sucrose by fructose. 
2.3.1 Effect of fructose consumption on glycaemic control: Intervention trials 
 
The finding that acute fructose feeding elicited a lower glycaemic response in comparison to 
sucrose and glucose led to studies investigating whether chronic fructose feeding would 
improve markers of glycaemic control and overall glucose metabolism.  
A meta-analysis of eight controlled feeding trials evaluated the effect of fructose on 
glycated haemoglobin (HbA1c) (Livesey and Taylor, 2008). HbA1c is considered to be the 
gold standard for assessing glycaemic control (Phillips, 2012). The majority of studies 
analysed compared fructose with carbohydrates such as starch and maltodextrin with one 
study using glucose as a comparator. The results showed that fructose intakes of ≥ 90 grams 
per day (g/d) had a beneficial effect on HbA1c. This was dependent on the dose of fructose, 
treatment duration and the severity of the dysglycaemia, with greater effect seen with 
increased dysglycaemia. However, fructose intake of ≥50 g/d was noted to be associated 
with significantly increased postprandial triacyglycerol.  
Another meta-analysis of 18 feeding trials evaluated the effect of fructose on glycated blood 
proteins and fasting glucose (Cozma et al., 2012). Trial characteristics varied in study 
duration (eight days to 52 weeks), fructose dose (22.5 to 137 g/d) and fructose comparators 
(77% of comparisons made against fructose were with starch, 7.7% with sucrose). There was 
a significant reduction in the percentage of glycated blood proteins (SMD (standardised 
mean difference) -0.27 (95% CI -0.49,-0.04) p=0.02) in those with type 1 (T1DM) and type 2 
diabetes (T2DM). Stratified analyses showed this reducing effect to be significant in those 




0.34, 0.09) P=0.24). There was no significant reduction in fasting blood glucose (SMD -0.40 
mmol/L (95% CI -0.83, 0.03) p=0.07) in those with T1DM and T2DM combined and when 
analysed separately. There was generally a significant amount of inter-trial heterogeneity 
present in this meta-analysis.  
 Both meta-analyses have included trials in which fructose was compared mainly against 
starch. The results therefore do not provide insight into how fructose affects glycaemic 
control in comparison to sucrose and glucose.  The effect of fructose on markers of 
glycaemic control should be considered in comparison to sucrose and glucose if fructose is 
to partially replace these sweeteners.  
A randomised crossover test meal study comprising 12 participants with T1DM and 12 with 
T2DM investigated the effects of fructose in comparison with sucrose on glycaemia (Bantle J 
et al., 1986). The two isocaloric, weight-maintenance diets were tested over eight days 
each; sucrose comprised 23% of total carbohydrate (CHO) in one diet, and fructose 
comprised 21% (137g/d) of total CHO in the other. On days seven and eight of each diet, 
plasma glucose was tested before, 60 and 120 minutes after meals. Statistical significance 
was ascertained using Tukey’s test (Honest significant difference). In participants with 
T1DM, there was a significant reduction in pre-prandial plasma glucose after the fructose 
intervention, relative to sucrose. This is of interest, the clinical implication being that the 
fructose diet may have improved glucose metabolism and glycaemic control over just eight 
days. Both groups experienced significantly reduced one and two hour post-prandial plasma 
glucose compared to sucrose. Overall mean plasma glucose values between the test diets 
decreased by 31% in the fructose diet in those with type 1 diabetes, and by 10% in those 
with T2DM.   
An intervention study investigated the effect of fructose feeding in seven participants with 
T2DM (Crapo et al., 1986). For 17 days prior to the study, participants’ usual sucrose intake 
was adjusted to an amount comparable to the fructose dose used in the study; this 
comprised 24% of total CHO consumed in the test diet (80-115 g/d). Following this, sucrose 
was replaced with fructose for two weeks. Glucose response was measured following oral 
glucose (OGTT) and fructose tolerance (OFTT) tests and post-consumption meal profiles 




as 50 grams of the respective sugar in 300 ml volume. Each of the meals contained 
approximately 16 grams of the respective added sugar. For the OGTT, nAUC (area under the 
curve) was significantly different between day three and 14 of the fructose diet (p<0.05) but 
not for baseline glucose response. There were no significant differences in serum insulin. 
The nAUC for serum glucose following fructose-containing test meals were significantly 
lower than the sucrose containing meals at both days three (p<0.05) and 14 (p<0.001). 
 A similar study was conducted in 11 normoglycaemic participants (Crapo and Kolterman, 
1984). However, participants were assigned to the sucrose control diet for only three to four 
days and then consumed the fructose treatment diet for two weeks. This study design was 
considered unsuitable for this literature review due to the differing duration of control and 
treatment groups. This protocol doesn’t give participants equal exposure to sucrose and 
fructose, thereby producing results that don’t accurately represent the effect of fructose in 
comparison to sucrose/producing an invalid comparison of fructose and sucrose’s effects on 
glycaemia.   
A study conducted by Thorburn et al investigated the long term effect of fructose on glucose 
tolerance(Thorburn et al., 1990). Six participants with T2DM followed a weight-maintaining 
sucrose-containing diet (13% energy, 76-124 g/d) for a minimum of five days. During 
baseline, fasting plasma glucose, serum insulin, HbA1c and glucagon levels were measured 
after four tolerance tests; an eight hour post-consumption meal profile (16 g sucrose added 
to each meal), an identical meal but with fructose replacing all sucrose, a three hour OGTT 
and a three hour OFTT. These tests were repeated on days 50 and 100. Following baseline 
studies, all sucrose in the diet was replaced by fructose. Weekly fasting plasma glucose was 
measured during the study. A hyperinsulinaemic, euglycaemic clamp study was also 
conducted over three hours on day 0 and 100 to measure differences in glucose metabolism 
and insulin sensitivity. Insulin was infused at 860 pmol/m-2/min to assess peripheral glucose 
disposal and suppressibility of hepatic glucose output, while plasma glucose was maintained 
at 4.8 mmol/L by an infusion rate of 20% glucose.  There was no significant overall change in 
mean fasting weekly plasma glucose concentration or in fasting plasma glucose, serum 
insulin and glucagon or HbA1c. This was associated with the unexplained rise in plasma 
glucose concentration in two participants; other participants’ plasma glucose and HbA1c 




withdrawn from the study due to the development of high triglyceride levels. There were no 
significant differences in AUC of fructose meals for plasma glucose within the fructose 
intervention.  During the hyperinsulinaemic euglycaemic clamp study, both plasma glucose 
and serum insulin were maintained at similar levels at day 0 and 100, without changes in 
basal hepatic glucose output. In the insulin stimulated state, peripheral glucose disposal 
rates were not significantly different between day 0 and 100. There was no difference in 
suppressibility of hepatic glucose output to equivalent hyperinsulinaemia. 
While the short term effect of fructose feeding has shown to confer a lowered glycaemic 
response in relation to sucrose and glucose evidenced through glycaemic index testing, the 
effect of fructose replacement on glycaemic control is unclear. Sucrose replacement for 
fructose has not shown to significantly change or improve glucose metabolism over longer 
periods of time(Thorburn et al., 1990). Moreover, longer term fructose feeding in 
participants with T2DM was associated with deterioration of glycaemic control and lipid 
metabolism in two participants, who developed unexplained rises in fasting plasma glucose 
concentrations and another participant who developed high triglyceride levels halfway 
through the study (Thorburn et al., 1990). Thus, fructose replacement may even be 
inappropriate in those with compromised glucose metabolism.
Figure 0.1 Table 1  2.1 Intervention Studies investigating effect of 


















Crossover 9 normoglycaemic  
10 T1DM 
17 T2DM 
50 grams each of glucose, 
fructose and sucrose were 
tested separately, in drinks and 
in meals.  
Normoglycaemic, T1DM–Serum glucose and 
insulin response (0-60 minutes)  generally 
significantly reduced in fructose-sweetened 
meals and drinks when compared with sucrose 
and glucose tests (p<0.05) 
 
T2DM- Serum glucose and insulin response 
generally significantly reduced (0-60 minutes) in 
fructose-sweetened drinks relative to sucrose 
(p<0.05) but not glucose.  
Reduction in serum glucose response for 
fructose-sweetened meals compared to glucose-
sweetened meals (p=0.025-0.0005) but not 
sucrose-sweetened. Generally no significant 
difference in serum insulin for meals sweetened 





 10 Normoglycaemic 
12 T1DM 
10 T2DM 
Test meals each containing 42 
grams of glucose, fructose and 
sucrose tested on separate 
occasions.  
Fructose produced the smallest mean area 
increments in plasma glucose concentration 





Lee 1998 Acute 
(0-120 mins) 
 8 normoglycaemic Participants consumed each in 
random order, on separate 
occasions: 
25g, 50g, 100g Sucrose 
25g, 50g, 100g Glucose 
25g, 50g, 100g White bread 25g, 
50g Fructose 
50g  each glucose and fructose  
A reference drink containing 0 
CHO  
Fructose- Significantly reduced glycaemic 
response at 25 and 50 grams compared to the 
other treatments (P<0.05).  
Glycaemic response to 50g glucose and 50g 
fructose was not significantly different 
compared with 100g sucrose.  
Bantle 
1986 




21% total energy fructose-
derived (137 grams) 




T1DM – mean plasma glucose reduced by 31% in 
fructose diet relative to sucrose.  
T2DM – mean plasma glucose reduced by 10% in 
fructose diet relative to sucrose. 
Crapo 
1986 










2 isocaloric, weight-maintaining 
test diets.  
24% of total CHO as sucrose   
24% of total CHO as fructose 
(80-115 g/d)  (2 weeks) 
50g OGTT: Total AUC was significantly different 
between day 3 and 14 (p<0.05). No significant 
difference in insulin observed. 
50g OFTT: Serum glucose response was not 
significantly different. Total AUC for serum 
insulin was significantly lowered from baseline 
to both days 3 and 14 (p<0.05).  
Meal response profile- Total AUC for glucose was 
significantly different between baseline and day 
3 (p<0.05) and baseline and day 14 (p<0.001). No 
significant differences observed for insulin 









3 months Controlled 
trial 
6 T2DM 13% (76-124 g/d)  total energy 
from  fructose as part of a 
weight maintaining diet 
No overall significant difference in mean plasma 
glucose, serum insulin and glucagon and HbA1c. 
Two participants had unexplained increase in 
glucose concentration by study end. Other 
participants generally trended towards reduced 
mean plasma glucose and HbA1c.  
Meal profile response- There was a significant 
reduction in AUC for plasma glucose between 
sucrose and fructose meals when day 0 and 100 
analysed together (p<0.025). No significant 
difference in AUC within fructose meals.  
 
Hyperinsulinaemic Euglycaemic clamp study – 
No significant difference in both plasma glucose 
and serum insulin concentrations; both were 
maintained at similar levels between day 0 and 
100. No change in basal hepatic glucose output 




2.4 Fructose and Uric Acid  
 
The metabolism of fructose can lead to the hepatic production and increased circulating 
concentration of UA (Choi et al., 2005). The ATP-dependent first step of fructose 
phosphorylation degrades ATP to adenosine diphosphate (ADP) and depletes intracellular 
phosphate (Lieberman et al., 2013). This causes ADP to convert to adenosine 
monophosphate, catalysed by the enzyme adenylate kinase. Low levels of phosphate 
stimulate the enzyme AMP deaminase, which drives the conversion of AMP to Inosine 
monophosphate (IMP), which is the precursor to UA (Lieberman et al., 2013). The nitrogen 
base of IMP, hypoxanthine is oxidised to xanthine, which is then oxidised to produce UA 
(Lieberman et al., 2013).  
 
   Figure 2.3 Fructose-driven production of UA (Johnson et al., 2013) 
 Excessive levels of UA in the blood, referred to as hyperuricemia is one of the most 
important risk factors in the development of gout, a painful inflammatory arthritis 
(Lieberman et al., 2013;Choi et al., 2005). On the other hand, UA has antioxidant properties 




3% of the population and is more prevalent in Māori and Pacific Island populations, with 
>25% prevalence in Māori and Pacific men 65 years and older (Winnard et al., 2012). High 
intakes of purines contained in foods such as meat and seafood have been identified as risk 
factors for gout (Choi et al., 2005). 
Hyperuricemia has also been associated with increased risk of developing features of 
metabolic syndrome (Rho et al., 2011). A study conducted in a US cohort of 8669 adults 
found the prevalence of metabolic syndrome, as defined by NHANES III, to increase by 19% 
for serum urate levels <6 mg/dL (530 µmol/L) to 71% for levels >10 mg/dL (880 µmol/L)(Choi 
and Ford, 2007).  
2.4.1 Effect of fructose on Uric Acid: Observational trials 
 
As fructose can increase UA levels, there was concern that fructose consumption may lead 
to hyperuricemia; consequently, associations between fructose and uricemia have been 
explored.  
Dietary intake, health status, demographics and blood chemistry data were extracted from 
NHANES 1999-2004 databases (Sun et al., 2010). Hyperuricemia was defined as having UA 
concentration >8.4 mg/dL (742 µmol/L) in men and >7.5 mg/dL (663 µmol/L) in women. The 
cohort comprised 9384 adults aged between 20 to 80 years, without diabetes, cancer or 
heart diseases. Fructose intake was assessed by summing the intake of naturally occurring 
unbound fructose and fructose from added sugars such as sucrose and HFCS (50% of added 
sugars). Fructose intakes were categorised as follows: ≤24.29, ≤41.23, ≤64.11 and >64.11 
g/d. In terms of contribution to total energy, the intake categories correspond to ≤ 5.48, ≤ 
8.28, ≤ 11.48 and >11.48 respectively. 2.6% of the cohort was considered hyperuricemic. 
There was no association between total fructose intake and risk of hyperuricemia even after 
adjusting for several confounders, such as sex, age, BMI and vitamin C intake. Using the 
lowest quartile of fructose intake as the reference (1.00), the adjusted odds ratio for the 
highest consumption quartile was 0.603 (95% CI 0.36-1.02). In contrast to the hypothesis 
that increasing fructose intake would be associated with higher risk of hyperuricemia, 
consumption quartiles above the reference tended to have a lower risk of hyperuricemia (all 




The effect of fructose intake on risk of hyperuricemia has also been investigated in an older 
cohort of 2570 participants (≥50 years) using NHANES III data (Choi et al., 2008). In this 
study, hyperuricemia was defined as >7 mg/dL (618 µmol/L) in men and >5.7 mg/dL (503 
µmol/L) in women. Daily total fructose intake was categorised into quartiles; <10 
(reference), 10-49.9, 50-74.9 and >75 g/d. The increase in serum UA with reference to the 
lowest fructose intake group was 4.42, 38 and 77.8 µmol/L with increasing intake, 
respectively (p for trend=0.003).  The odds ratio of being hyperuricemic according to the 
fructose consumption quartiles were 1.03, 2.05 and 4.11 (p for trend 0.003).  
A number of studies have investigated the relationship between SSB intake and 
hyperuricemia (Lin et al., 2012;Nguyen et al., 2009). In general, increasing SSB intake has 
been associated with increasing UA levels. However, as fructose intake was not determined 
in these trials, it is unclear whether the associations found were attributable to the fructose 
component of the SSB’s or other dietary or lifestyle factors.  
From the findings described above, it is unclear whether fructose is associated with risk of 
hyperuricemia. The older cohort in Choi et al’s study comprised mainly of older participants 
≥ 50 years, with a higher prevalence of hyperuricemia (18%) compared to the cohort in Sun 
et al, which had younger participants and an overall decreased prevalence of hyperuricemia 
(2.6%). Increasing age is known to be a risk factor in the development of hyperuricemia 
(Choi et al., 2005).  The inconsistent findings between the two studies may also be related to 
the nature of cross sectional studies which don’t provide a temporal perspective on the 
relationships between exposures and outcomes, unlike prospective studies that follow 
participants for longer time frames of months and years. With the older cohort, it is not 
known what fructose consumption patterns have been followed over a longer period of 
time. The reference fructose intake of 10 g/d used could also be considered too low to 
represent a reference group. The lowest total sugar intake for the 10th percentile in the 
2008/09 NZ ANS is 30 grams (University of Otago, 2011). This comprises of all mono- and 
disaccharide sugars from fruit and vegetables, non-alcoholic beverages and milk. This 
reference amount is also less than half of the fructose reference group used in Sun et al’s 
study (24.9 g/d), which questions whether these results can be compared together.  





Studies have compared the effect of fructose consumption on UA in intervention studies. 
Studies have varied in the amount of fructose used and study duration, producing different 
effects.  
The acute effect of fructose and glucose-sweetened drinks on plasma UA was investigated in 
a randomised crossover trial with 42 healthy participants (Carran et al., 2016). Beverages 
were sweetened with 26.7 grams of fructose or glucose.  UA increased significantly from 
baseline to 30 (15µmol/L, p<0.001) and 60 minutes (14µmol/L, p=0.008) following fructose 
drink consumption respectively.  The glucose drink elicited a significant lowering effect at 60 
minutes post-consumption (-8µmol/L, p=0.032).  A drink containing 15.8 grams fructose also 
elicited a significant increase at 30 (7µmol/L, p=0.021) and 60 minutes (4 µmol/L, p=0.028). 
While the acute effect of fructose intake in this trial produces a significant transient increase 
in plasma UA, the glucose control drink contributes a significant lowering effect. There is a 
question of whether acute rises in UA necessarily contribute to chronic impact on UA.  
Longer term effect of fructose on UA was investigated in seven participants with T2DM over 
two week study duration (Crapo et al., 1986). The studies had two phases: baseline and 
fructose.  Participants were given weight maintenance diets, with sucrose incorporated as 
24% of total carbohydrate (80-115 g/d).The amount of sucrose given in the baseline weight 
maintenance diet was adjusted to mimic usual sucrose consumption in the patients’ diet. 
Participants consumed this diet for 17-18 days. For the next 14 days, participants consumed 
the same diet, with fructose replacing sucrose. Serum UA was measured at baseline and 
after the 2 week study period. There was no significant increase (8.8µmol/L) in those with 
T2DM.  
A similar study protocol was followed by Crapo et al in 1984 with healthy participants 
however; the baseline study period was only three to four days followed by a fructose 
intervention of 2 week duration. Due to differences in intervention exposure, this trial was 
considered unsuitable for comparison of fructose and sucrose on uric acid response in this 
literature review (Crapo and Kolterman, 1984).  
The study by Crapo et al in 1986 showed that fructose intake in isocaloric conditions did not 




feeding with fructose. There was no significant difference in UA at baseline to study end in 
participants with T2DM. The effect of fructose on UA in hypercaloric doses has also been 
investigated.  
11 healthy participants took part in three crossover interventions, each one week in 
duration; a weight maintenance diet by itself or supplemented with fructose or glucose 
corresponding to 35% energy requirement (approximately 213 g/d) (Ngo Sock et al., 2010). 
A two to three week washout period was implemented between interventions. Compared 
to weight maintenance diet alone, plasma UA had increased significantly in both glucose 
and fructose interventions (p=0.05).  
The observation that UA levels increased following hypercaloric doses of glucose as well as 
fructose point towards the possibility of excess energy contributing to increased levels, as 
fructose did not appear to increase UA in isocaloric trials.  
The overall effect of fructose intake in comparison to other sources of carbohydrate (starch, 
sucrose and glucose) on UA was investigated in a meta-analysis of 21 feeding trials (Wang et 
al., 2012). 18 isocaloric and three hypercaloric trials were included. The mean dose of 
fructose in isocaloric trials was 94 g/d (range 25-213 g/d) corresponding to 5-33% energy, 
and 215 g/d (213-219 g/d) in hypercaloric trials. There was no significant effect of fructose 
on UA found when exchanged for other carbohydrate sources in those with pre-
diabetes/diabetes (mean difference (MD) -4.09 µmol/L) or without diabetes (MD 1.28 
µmol/L). However, there was a significant effect of fructose on UA levels in hypercaloric 
trials (MD 31µmol/L). There was no evidence of inter-trial heterogeneity in isocaloric and 
hypercaloric analyses.  
The findings of isocaloric longer term fructose feeding trials appear consistent in that 
fructose does not significantly raise UA in comparison to sucrose. The effect of fructose 
intake appears to depend on the amount of fructose given in the context of energy 
requirement. Isocaloric intake of fructose has shown a consistent lack of harm whereas 
hypercaloric intakes are associated with an increase in UA levels. Given this, it is reasonable 
to assume that the transient rises seen after fructose feeding in an acute setting does not 




 Table 2.2 Intervention Studies investigating effect of fructose on UA response in comparison to sucrose and/or glucose 
Author (Year) Length of study  Study design  Treatment and dose Participants Results 






26.7 grams fructose (Sprite 600ml)  
15.8 grams fructose (Sprite 355ml) 
26.7 grams fructose (600ml)   
 
41 healthy Fructose(non-Sprite)- UA 
increased by 15 µmol/L (95% 
CI 10,21) from 0-30 minutes 
(p<0.001) 
 
Sprite 355ml-UA increased 
by 7µmol/L (95 % CI 1,12 
p<0.021) 
Crapo (1986) 2 weeks  Randomised 
controlled  
crossover trial 
Participants consumed 2 isocaloric, 
weight-maintaining test diets.  
24% of total CHO as sucrose (2 weeks) 
24% of total CHO as fructose (80-115 
g/d) (2 week feeding) 
7 with T2DM 
 
No significant difference in 
UA at baseline, day 3 (+44.2 
µmol/L) or 14 (+8.84 µmol/L) 
Ngo Sock 
(2010) 






Weight-maintaining diet supplemented 
with glucose (+35% excess energy 
Weight maintaining diet supplemented 
with fructose (+35% excess energy) 
11 healthy males  UA was significantly raised in 
both glucose and fructose 
supplemented diets when 
compared to the weight 
maintaining diet (P<0.05).  











Mean fructose dose 
Isocaloric trials=94 g/d(25-213 g/d) 





N= 271 healthy 
Isocaloric trials:  
Those with diabetes= -4.09 
µmol/L)  
Without diabetes (MD 1.28 
µmol/L). 





2.5 Fructose and Blood Pressure 
 
High BP was the leading risk factor for global disease burden in a 2010 review of global 
disease data (Lim et al., 2012). Trials in which animals were given high fructose diets of 
approximately 60% total energy resulted in increases in BP; leading to speculation that 
fructose intake in humans may have similar effects (Martinez et al., 1994;Singh et al., 2008). 
The effects of fructose feeding in humans have been investigated.  
2.5.1 Fructose and Blood Pressure: Observational trials 
 
Data from 3 cohorts (n=223 230) was analysed to investigate the association of fructose 
with risk of developing hypertension (Forman et al., 2009). The median intake of fructose 
was 9.2% and the age of participants ranged from 25-55 in women and 40-75 in men. 
Dietary information was collected using a validated FFQ. Total caloric intake of fructose was 
calculated as the percentage of calories obtained from free fructose and half the calories 
from sucrose. SSB represented 19.8% of fructose consumed; other sources of fructose were 
fruit juices (18.4%) and fruits such as apples (11%), bananas (6%) and oranges (3.2%).  
Fructose intake was classified into quintiles of percentage of total energy intake as follows: 
5.8%, 7.8%, 9.4%, 11.1% and 14.2%. There was no overall association of fructose intake and 
risk of hypertension. When the highest quintile of fructose intake was compared with the 
lowest, the multivariable relative risks (95% confidence interval) were 1.02 (0.99 to 1.06) in 
Nurses’ Health Study 1, 1.03 (0.98 to 1.08) in Nurses’ Health Study 2, and 0.99 (0.93 to 1.05) 
in Health Professionals Follow-up Study.  
Another study used data obtained from NHANES 2003-2006 to measure the added fructose 
intake of 4528 participants, determined from a FFQ (Jalal et al., 2010). Median fructose 
intake was 74 g/d (IQR 40-133g/d) in the form of sucrose and HFCS. Only foods with high 
fructose content from added sugars were included, including dried fruit, however natural 
fruit intake was excluded from the analysis. Results were classified according to clinically 
relevant systolic BP cut offs; >120 (normal), 120-139 (prehypertension), 140-159 (stage 1 
hypertension) and ≥160 (stage 2 hypertension) mmHg. 30% of the study population were 
pre-hypertensive while 2% had stage 2 hypertension. There was a significant trend towards 




g/d was associated with a 36% increased risk (odds ratio (OR) 1.36) for those with stage 1 
hypertension and more than double (OR 2.10) for those with stage 2 hypertension.  
An important difference between the studies is the source of fructose studied. Forman et al 
quantified total fructose intake from natural and added sources, whereas Jalal et al 
specifically examined fructose from added sugar. The types of food sources were fruit juices, 
SSB, baked goods and confectionery, which contribute energy into the diet. Indeed, fructose 
from fruit was excluded from the analyses due the confounding effect of other nutrients 
such as naturally present potassium.   
2.5.2 Fructose and Blood Pressure: Intervention Studies 
 
Studies have explored the effect of fructose on BP (BP) in various settings, using different 
amount of fructose.  
The acute effect of fructose and glucose ingestion on BP was studied in 15 healthy 
participants (Brown et al., 2008). Participants consumed three different treatments on 
separate occasions; water, water containing 60 grams of fructose and water containing 60 
grams of glucose, each made up to 500ml. BP was monitored continuously 30 minutes 
during a baseline period and 120 minutes after consuming the treatment. The glucose drink 
had no significant effect on BP, however fructose significantly raised BP within 30 minutes of 
consumption (p<0.01), reaching a peak of 6.02mmHg above baseline, with elevation 
maintained for the duration of measurement (120 minutes).  
Another study examined the acute effects of fructose, glucose and sucrose in 12 healthy 
participants (Grasser et al., 2014). Participants consumed four different treatments on 
separate occasions; 60 grams fructose, 60 grams glucose, 60 grams sucrose and 30 grams 
fructose. Treatments were dissolved in water to make a 500ml beverage. BP was monitored 
similarly as described in the study above, however BP was only measured for 60 minutes 
post-consumption. Both doses of fructose resulted in significant elevation of systolic BP 
(SBP), diastolic BP (DBP) and mean BP (MBP). SBP peaked at 7.1 mmHg (p<0.05) with 60g 
fructose and 5.4 mmHg (p<0.005) with 30g fructose. The glucose drink raised SBP over time 




While a transient rise in BP might occur in acute settings post-fructose consumption, a more 
clinically relevant outcome concerns chronic increased BP. Several longer term studies have 
explored whether fructose consumption is associated with chronic increase in BP. 
A total of 267 participants were randomly assigned to one of four interventions for 10 
weeks; fructose, glucose, sucrose or HFCS added to milk. Fructose and glucose were given as 
9% of weight maintenance calories, sucrose and HFCS given as 18% weight maintenance 
calories (Angelopoulos et al., 2015). All sugars were added to low-fat milk. Participants were 
given instruction on how to account for the calorie intake from the treatments however 
they followed an ad libitum diet. Overall, there was a decrease in resting BP for the whole 
cohort (SBP -3, DBP -1.7 mmHg). There was no significant difference between sugar 
treatments (interaction p>0.05).  
The effect of fructose, glucose and sucrose on BP was investigated in a crossover trial 
(Aeberli I et al., 2011). In this study, 29 healthy participants were randomised to 6 different 
treatments, each lasting 3 weeks in duration: moderate fructose (40 g/d), high fructose (80 
g/d), moderate glucose (40 g/d), high glucose (80 g/d), high sucrose (80 g/d) and dietary 
advice to reduce free fructose intake, by restricting fruit and vegetables high in fructose, 
honey and dried fruit. Each intervention had a washout period of four weeks. There was no 
change in SBP or DBP by the end of the study. The only interventions to increase BP was 
moderate glucose (SBP +0.6 mmHg) and high sucrose (SBP +1 mmgHg). High fructose 
treatment resulted in a 1 mmHg decrease in SBP.  
The effect of fructose on BP in a hypercaloric setting was investigated in seven healthy 
participants over 4 weeks (Lê et al., 2006). During baseline studies (two weeks), participants 
consumed an isocaloric diet, restricting sucrose (<20 g/d fructose) and artificial sweeteners. 
Participants then added 1.5 g of fructose per kilogram of body weight per day for four 
weeks (approximately 104 g/d) to their diet, consumed as a SSB. By the end of the study, 
mean BP was not significantly changed (+1 mmHg) from baseline to study end.  
Hypercaloric fructose and glucose feeding was investigated in a randomised controlled trial 
comprising 35 normoglycaemic, overweight/obese participants consuming glucose (n=18) or  
fructose-sweetened (n=17) test drinks corresponding to 25% daily energy (125-180 grams) 




with an ad libitum diet, and for two weeks in an inpatient unit as part of an energy balanced 
diet. BP did not change significantly in either treatment group.  
While BP has been shown to increase in acute feeding settings, longer term trials, including 
those that feed hypercaloric doses of fructose, present a lack of evidence for fructose-
induced chronic increase BP.  
The overall effect of fructose on BP has been reviewed in a meta-analysis of 13 isocaloric 
and two hypercaloric trials (Ha et al., 2012). Trials were included if they investigated 
isocaloric or hypercaloric fructose intake compared with other sources of carbohydrate 
(HFCS, glucose, sucrose and starch) on SBP, DBP or mean arterial pressure (MAP) for a 
minimum of 7 days. Six isocaloric trials used starch as a comparator, seven used glucose, 
one used HFCS and 1 used sucrose. The median dose of fructose was 78.5 g/d (range 53-182 
g/d) and median follow up period was four weeks (range 15.5 days-10 weeks). Hypercaloric 
trials administered fructose at a median dose of 143 g/d (range: +18-25% energy) and 
median follow up was 7 weeks (range 4-10 weeks). In isocaloric trials, there was no effect in 
overall for SBP (MD -1.10 95% CI -2.46 to 0.44), a significant lowering effect for DBP (MD -
1.54 95% CI -2.77 to -0.32) and MAP (MD -1.16 95% CI -2.15 to -0.18) in those without 
diabetes. There was no overall effect of fructose feeding on MAP in hypercaloric trials.    
With the exception of one trial, all trials that used glucose, sucrose and HFCS  as fructose 
comparators favoured fructose in the lowering of SBP, DBP and MAP in those without 
T2DM.  
The overall finding of this meta-analysis presents a beneficial effect on BP, from fructose 
feeding in isocaloric exchange with other carbohydrate sources, especially in comparison 
with sucrose, glucose and HFCS. The dose of fructose given doesn’t appear to affect BP 
outcomes, with both moderate doses (78.5g/d) and high doses (182 g/d) generally 
conferring a lowering effect on BP. Trial duration doesn’t appear to affect BP outcomes 
either, with shorter trials (15.5 days) and longer trials (10 weeks) having the same effect of 
lowering BP.  
The doses of fructose used in the intervention studies are generally higher than the median 
fructose consumption (49 grams) in NZ, presenting findings that cannot be extrapolated to 




carbohydrate sources presents a lack of harm on BP, and even a beneficial lowering effect in 
meta-analysis findings. Trials that use a fructose dose amount approximate to NZ median 
fructose intake, in isocaloric exchange with glucose and sucrose would provide results that 


















Figure 0.1 Table 2.3 Intervention Studies investigating effect of fructose on BP response in comparison to 
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15 healthy  No significant change in BP post-
glucose treatment. 
Fructose significantly raised BP 
(6.02mmHg) within 30 minutes of 
consumption (p<0.01). Elevation 
was maintained  during BP 
measurement (120 minutes). 







      12 Healthy    60g fructose: SBP increased by 7.1 
mmHg (p<0.05) 
30g fructose- SBP increased by 5.4 
mmHg (p<0.005)  
60g glucose – SBP increased by 
2.5mmHg (p<0.05)  
Angelopoulos 
(2015) 
10 weeks  Randomised 
controlled  
intervention trial 
 9% total calories (TC) from 
fructose 
9% TC from glucose 
18% TC from sucrose 




Decrease in BP for all cohorts 
No significant difference between 
treatments  
Aeberli (2011) 3 weeks per 
intervention  
Crossover  40 g/d fructose 
80 g/d fructose 
40 g/d glucose 
80 g/d glucose 
Dietary advice to reduce 
free fructose intake  
 29 healthy 
 
No significant change in SBP or DBP 






Le (2006) 6 weeks (2 wks 
baseline + 4 wks 
fructose) 
Crossover 7 healthy 1.5g fructose per 
kg body weight 
(approx. 104 g/d) 
<20 g/d fructose 




10 weeks Randomised 
intervention 
35 healthy 125-180 g/d 
fructose (+25% 
excess energy) 
No significant change in SBP  
(+1mmHg) or DBP (-1 mmHg) 
Ha (2012) Range=15.5 days 












diabetes (n=333), with 
diabetes/pre-diabetes 
(n=19) 
Hypercaloric= 24 without 
diabetes (n=24) 
 






In those without diabetes; no 
overall effect on SBP (MD -1.10 95% 
CI -2.46 to 0.44) 
Significant lowering effect for DBP 
(MD -1.54 95% CI -2.77 to -0.32) and 
MAP (MD -1.16 95% CI -2.15 to -
0.18) 
 
Those with diabetes/pre-diabetes; 
No significant effect on SBP, DBP or 
MABP 






2.6 Fructose and Chronic Disease 
 
Fructose consumption has been associated with developing features of metabolic syndrome 
which include dyslipidemia (Stanhope et al., 2009;Silbernagel et al., 2011), visceral adiposity 
(Stanhope et al., 2009) and decreased insulin sensitivity (Stanhope et al., 2009;Elliott et al., 
2002).  
The increased consumption of fructose and the prevalence of obesity-related chronic 
disease such as diabetes and cardiovascular disease during the late 1970’s led to speculation 
that fructose consumption was to blame for negative health outcomes (Thornley et al., 
2012;Bray, 2010;Hu, 2013).  
Indeed, visceral adiposity, dyslipidemia, decreased insulin sensitivity were increased in 
overweight/obese adults who were supplemented with a fructose-sweetened beverage that 
provided 25% of their energy requirements when compared against those consuming an 
isocaloric glucose-sweetened beverage over eight weeks (Stanhope et al., 2009).  
Conversely, Livesey et al found the dose amount an important factor to consider when 
assessing fructose effect on lipid profile. Dose amounts of <100 grams per day had no 
significant effect on fasting plasma triacylglycerol (FPTG) however up to 350 grams per day 
resulted in increased FPTG in both randomised and non-randomised trials (Livesey and 
Taylor, 2008). Dose amounts of over 100 grams per day showed significant increase in body 
weight (0.44 kg/week, p<0.018) but showed no effect was seen for an oral fructose intake of 
<100 grams per day.  
The average intake of fructose in NZ, the USA and the Netherlands is <100 grams of fructose 
per day. Thus, studies that examine fructose effect on health outcomes using >100 grams 








3 Methods  
3.1 Ethics 
 
This study was approved by the University of Otago Human Ethics committee and granted 
permission to recruit participants from the general public (Appendix A). Māori  Consultation 
was sought; a consultation form was submitted to Ngāi Tahu (Appendix B) . Potential 
participants were asked to read the information sheet, were informed of the criteria 
required for participation, relevant risks and study protocol. Participants were encouraged 
to inquire about the testing details if they had any uncertainties around testing procedures.   
All participants were screened for eligibility using the exclusion criteria and signed a consent 
form.  
3.2 Participants  
 
3.2.1 Sample Size Calculation 
 
 The study was powered to detect a 30% difference in incremental area under the curve (iAUC) 
between the sucrose reference and the test beverages. A difference of 30% iAUC has been 
associated with clinical benefit (Wolever et al., 1992). In this study, a sample size of 11 was 
adequate to detect a 30% reduction in iAUC with 80% power using the 5% level of 
significance. A sample of 12 was also sufficient to detect a 50% difference in uric acid AUC between 
reference and test beverages. Blood pressure was a secondary outcome and the study was not 
powered for this factor. 
3.2.2 Recruitment    
 
Participants were recruited from the general public using flyers that detailed the premise of 
the study, study protocol, participant criteria and reimbursement. Participants were eligible 
to participate if they were not pregnant, or been diagnosed with diabetes mellitus, 
cardiovascular disease, cancer, diseases of the digestive system, were free from food 






Participants who completed the test protocol were given $100 supermarket vouchers. 
3.3 Test protocol  
 
3.3.1 Test and reference beverages  
 
Participants were given sugar sweetened beverages to drink on five occasions. A reference 
beverage was tested on two occasions as a duplicate test and three test beverages were 
each tested on one occasion. The reference beverage was sweetened with 50g sucrose 
(Caster sugar, Pams NZ). Beverages were designed to contain sugar concentration of 10.9% 
which is commonly use in commercially manufactured SSB (Ventura et al., 2011). The test 
beverages comprised a blend of sugars in the following proportions: 
 33.5g sucrose and 16.5g fructose (67S:33F) 
 25g sucrose and 25g fructose (50S:50F) 
 16.5g sucrose and 33.5g fructose (33S:67F) 
The sugar blends were prepared before testing days in bulk and placed into re-sealable 
collection bags. They were then passed on to a staff member of the Human Nutrition 
department who re-labelled the treatments by colour, so as to blind participants and 
investigators to the treatments given on testing days. On the morning of each testing day, 
the respective treatment was placed in to a measuring cylinder and topped with sparkling 
water (Budget, Foodstuff Ltd NZ) that had been refrigerated overnight. Each treatment was 
made to 450ml and participants were requested to consume this within the first 15 minutes.  
3.3.2 Participant Randomisation  
 
The order in which the treatment beverages were received was randomised to each 
participant. Randomisation was conducted to ensure that each participant followed a 




Participants were reminded the night before their test day to maintain an overnight fast 
from 10pm until 7am, with the exception of consuming drinking water. Participants arrived 
at the Department of Human Nutrition Clinic at 7am and were seated for approximately 20 
minutes while the testing session was being prepared. This also gave participants a chance 
to relax and for blood glucose concentrations and BP to stabilise if they had walked or 
cycled to the clinic.  
Participants were then prepared for the collection of blood and BP measurements. 
Participants were asked to wear clothing in which the sleeves could be easily rolled back. 
Blood draws were typically collected from the arm that participants chose however, if there 
was difficulty in inserting the cannula, the other arm was chosen by default. 
3.3.3 Blood collection and BP measurement 
 
The candidate was trained by the Department of Human Nutrition research nurse to draw 
blood from the venous cannula (BD Insyte™, Utah USA). Blood draws were thereafter 
carried out by both the research nurse and the candidate. Drawing of blood and BP 
measurements was taken at baseline and thereafter at 15, 30, 45, 60, 90 and 120 minutes.  
The Department of Human Nutrition research nurse first applied a tourniquet on the upper 
arm that was to be tested and sanitised the testing area with an alcohol swab. A 20 gauge 
cannula was inserted into the vein in the anterior cubital fossa of each participant, which 
was immediately flushed with 10 millilitres of normal saline. The needle was then 
withdrawn, with the catheter left in the vein and secured with medical tape. An observation 
period of 10 minutes was implemented to ensure the correct placement of the cannula. 
Prior to the collection of the sample, an initial volume of 0.5ml was drawn and discarded to 
allow for dilution. Following this draw, 0.5 millilitres of blood was drawn for the sample 
after which the cannula site was flushed with sterile normal saline solution. Following this, 
the tourniquet was released, and blood samples were pipetted into collection tubes labelled 
with the participants ID and draw time. Blood samples were kept whole at room 
temperature and not treated with anti-coagulant.  
Baseline BP was collected using an OMRON digital automatic BP monitor, model HEM-907 




from the arm that wasn’t undergoing blood draws. Participants were prepared for BP 
measurement by sitting in a relaxed upright position with both feet placed on the floor. The 
participant’s arm was positioned with the palm of the hand facing upward and the cuff of 
the monitor kept at heart level.  
The cuff of the monitor was positioned over the brachial artery and the monitor was 
programmed to take a single measurement. The measurements were recorded by the 
candidate. Following this, the first blood draw was collected, and a timer was set for the 
next draw. Treatments were given as soon as the first draw had been collected. Blood 
samples were stored in airtight vials until the testing session was completed and ready for 
processing.  
3.3.4 Anthropometric data  
 
Weight and height measurements were collected in accordance with the ISAK (International 
Society for the Advancement of Kinanthrometry) guidelines by the candidate who holds a 
current Level 1 ISAK certificate. Participants were asked to remove their shoes and outer 
clothing prior to measurement. Weight was recorded to the nearest gram using electronic 
scales (Seca Alpha scale Model 770, California USA) and height to the nearest millimetre 
using a free standing calibrated stadiometer (Holtain Limited, Crosswell Wales).  
3.4 Processing of samples 
  
Analysis of blood samples was conducted in the Human Nutrition Diabetes and Lipids 
laboratory at the University of Otago. Whole blood samples were centrifuged at 2500 RPM 
for five minutes post-testing to collect only plasma from each sample. The plasma sample 
was then transferred to a 0.5ml screw-top collection tube and frozen at – 80 C until all 
samples had been collected. All samples collected contained sufficient amount of plasma 
required for testing of glucose and UA and therefore didn’t require any dilution. Analysis of 
glucose and UA concentration was carried out using a Roche Hitachi Cobas c 311 auto-
analyser (Roche Diagnostics, Indianapolis, USA).  





3.5.1 Method for assessing AUC  
 
 iAUC is a commonly used method for analysing responses over time.  It is calculated as the 
total incremental area from baseline to the last time point and ignores any area occurring 
below baseline. iAUC is useful for measuring hyperglycaemic phases in blood glucose 
response but is not sensitive in accounting for responses that deviate below baseline, and 
therefore doesn’t provide information on the overall response. In the figure below, the 
shaded area termed A is the iAUC.  
Figure 2 
 Figure 3.1 iAUC calculated as sum of areas in shaded portion "A" of hypothetical response 
curve 
 
 In the interest of quantifying the overall response produced by the study treatments, “net” 
area was also used to measure AUC for responses (nAUC). Net area is defined as subtracting 
area above baseline (A) from area below baseline (B) to produce a value that reflects the net 
response to the respective treatment (Gannon et al., 1989). It was felt that this method was 
more reflective of the overall response as it accounts for both aspects of the response and 
the resulting nAUC provides information on whether a treatment induces an overall effect 













3.5.2 Data Processing 
 
Data was entered into Microsoft Excel (Version 14.0.7166.5000, Microsoft Corporation 
2010) to calculate the iAUC (incremental area under the curve) and nAUC of glycaemic 
values and only nAUC for uricaemic and BP values.   
The iAUC and nAUC of the two reference treatments (i.e. sucrose-only beverages) was 
averaged to provide a set of reference values against which the other treatments were 
tested (i.e. iAUC and nAUC of combined sucrose values). A mixed effects regression model 
was used to determine if there were any significant differences between the sucrose 
reference against the fructose-containing treatment groups. The model was adjusted for 
treatment order, and also adjusted for sex for uric response analysis.  
iAUC values for glucose required log transformation, to reduce skew and improve the fit of 
the model. Log transformation was carried out having met the assumptions of the model, 
i.e. residuals were checked for homogeneity of variance. Log transformation was not 
required for testing differences between treatment groups for nAUC of glucose, UA and BP 
as this data fit the model appropriately.  
Statistical analysis was conducted using the statistical programme STATA/1C version 13.1 
(StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). 
Statistical significance was set at p=0.05. 
A 
B 
Figure 3.2 nAUC calculated as sum of area below baseline "B" from area about 






4.1 Participant Characteristics 
 
Data was collected from twelve participants, 7 males and 5 females, aged between 19 and 
39 years. Participants were predominantly of European ethnicity (n=9), Asian (n=2) and 
Middle Eastern (n=1). All participants were within the healthy (n=8) to overweight (n=4) BMI 
range; none were classified as underweight or obese.  
Fasting blood glucose and BP values of the five visits were averaged for each person and 
from these, group mean plasma glucose, UA and BP were calculated. All values were within 
the normal ranges for healthy individuals (Rho et al., 2011;Alberti and Zimmet, 
1998;Handler et al., 2012).  
 Table 4.1. Characteristics of study participants (n=12) 
 Characteristic Mean (SD) Healthy reference values 





23.9 (3.22) 18.5-24.9 








Baseline fasting plasma UA 
concentration (µmol/L)  
320 (73) Males ≤ 400  
Females ≤360 
   






Systolic 96 (3) 90-119 
Diastolic 65 (7) 60-79 
*Data are expressed as mean (standard deviation unless otherwise indicated) 
Abbreviations used: BMI=body mass index (calculated as body weight in kilograms divided 
by the square of height in metres); n=number of subjects 
 





Mean iAUC and nAUC for blood glucose response is presented in Table 2 and Table 3 
respectively. There was a significant trend for reduction in blood glucose response as 
proportion of fructose increased in the test drinks (p for trend <0.001). Reduction in iAUC 
was significant only for the 50S:50F and 33S:67F test drinks. For nAUC, reduction was only 
significant for the highest fructose treatment, 33S:67F.  
  Table 4.2. iAUC for post prandial glycaemic response 
Treatment Mean (SD)  Difference % (95% CI)† P-value P for trend 
Sucrose 100% 119.46 (75.84)    
67S:33F 90.99 (70.82) -20.5 (0.55,1.15) 0.228  
50S:50F 79.45 (64.88) -32.2 (0.46, 0.99) 0.045  
33S:67F  64.52 (54.64) -43.22 (0.38, 0.84) 0.004  
    <0.001 
†Difference is reported as a % reduction between iAUC 
  
 Table 4.3 nAUC for post prandial glycaemic response 
Treatment Mean (SD)  Difference (95% CI)† P-value 
Sucrose 100% 90.91 (95.26)   
67S:33F 71.26 (85.76) -18.35 (-60.04, 
23.34) 
0.388 
50S:50F 58.51 (82.68) -32.43 (-74.85, 9.98) 0.134 
33S:67F  41.42 (70.84) -44.72 (-88.1, -1.34) 0.043 







































 Figure 4.1. Mean changes in blood glucose response for sucrose, 67S:33F, 50S:50F and 
33S:67F. 
 
4.3 Uric Acid response  
 
Mean iAUC and nAUC for plasma UA response is presented in Table 4 and Table 5 
respectively. Increase in UA for fructose containing test drinks relative to sucrose was 
significant for both iAUC and absolute incremental AUC  (p=0.000).    
 Table 4.4 iAUC response for plasma UA 
Treatment Mean (SD)  Difference with 
sucrose (95% CI)† 
P value 
Sucrose 100% 1320 (1639)   
67S:33F 3062 (2665) 1826 (878, 2776) 0.000 
50S:50F 3647 (2122) 2570 (1419, 3395) 0.000 
33S:67F 3623 (2832) 2407 (1605, 3536) 0.000 
†Difference is reported as AUC units 
  Table 4.5 nAUC response for plasma UA 
Treatment Mean (SD)  Difference with 
sucrose  (95% CI)† 
P value 
Sucrose 100% 1211 (1701)   
67S:33F 3000 (2732) 1876 (865, 2888) 0.000 
50S:50F 3636 (2129) 2686 (1334, 3439) 0.000 
33S:67F 3468 (3054) 2386 (1656, 3715) 0.000 






Figure 4.2 Mean changes in plasma UA response 
 
4.4 Blood Pressure response 
 
Mean nAUC for BP response is presented in Table 6 and Table 7 respectively. Reductions 
between the fructose treatments and the sucrose reference were not statistically 
significant, apart from the highest fructose-containing treatment, 33S:67F (p=0.004).   
 Table 4.6 nAUC for systolic BP 
Treatment Mean (SD)  Differences (95% CI)† P value 
Sucrose 100% 738.8 (608.8)   
67S:33F 180.6 (756.5) -530.7 (-1073.2, 11.7) 0.055 
50S:50F 520.6 (965.7) -345.6 (-897.5, 206.4) 0.220 
33S:67F   57.5 (791.7) -835.3 (-1399.8, -270.8) 0.004 
†Difference is reported as AUC units 
  
 Table 4.7 nAUC for diastolic BP  
Treatment Mean (SD)  Differences (95% CI)† P value 
Sucrose 100% 298.8 (604.8)   
67S:33F   67.5 (540.1) -222.4 (-666.5, 221.6) 0.326 
50S:50F 323.8 (704.2) -53.9 (-505.8, 397.8) 0.815 
33S:67F 236.9 (867.9) -128.8 (-590.9. 333.2) 0.585 








































 Figure 4.3 Mean changes in systolic BP 
  
 





























































































This study is the first to test the effect of partial replacement of sucrose with fructose on 
glycaemic, UA and BP response. There was a trend for glycaemic response to decrease as 
the proportion of fructose increased, in a dose-response manner. This is consistent with 
previous studies that show fructose elicits a decreased glycaemic response compared to 
sucrose (Bantle et al., 1983;Crapo et al., 1980;Foster-Powell et al., 2002). In this study 
sample, the glycaemic response to the 33% replacement wasn’t significantly different 
compared to the sucrose control. In contrast, the UA response to the 33%, 50% and 67% 
was more than double that of the response to sucrose. For BP response, there was a general 
reduction in both systolic and diastolic BP, for all partially-replaced treatments relative to 
sucrose; however, the only statistically significant difference was seen in systolic BP when 
the highest level (67%) of fructose substitution was used.  
5.1 Glycaemic Response  
 
EFSA stipulates the manufacturers can bear a health claim when replacing a minimum of 
30% sucrose and/or glucose with fructose due to a lowered glycaemic response (Agostoni C, 
2011). The evidential substantiation of the health claim was based on complete 
replacement of sucrose with fructose. However, EFSA have permitted a health claim in 
which fructose is partially substituted for sucrose or glucose. Our data indicate that a 
significant reduction in glycaemic response is achieved when 67% and 50% of sucrose is 
replaced in a beverage with fructose. Using our study design, replacement of 33% didn’t 
result in statistically significant reductions of glycaemic response. However, a trend 
indicating dose-response reduction in glycaemic response was apparent across the various 
levels of substitution, suggesting that partial substitution of 33% of sucrose with fructose is 
likely to have a modest lowering effect on glycaemic response.  
Examination of glycaemic response on an individual level indicated that not all participants 
experienced lowered glycaemic response after consuming the 33% beverage; the PPG 
response of four of the twelve participants increased relative to the sucrose beverage. This 




response. The practical implication of partial-replacement of sucrose with fructose may 
include increased PPG response in some individuals.  There is a considerable amount of 
intra- and inter-individual variation when testing glycaemic response; this is generally 
evident in GI studies which can reduce this imprecision by repeated testing (Pi-Sunyer, 
2002;Williams et al., 2008). While it is established that the consumption of fructose 
produces a relatively lower glycaemic response compared to sucrose, it is likely that 
individuals will experience a range in PPG when 30% of fructose is partially substituted 
which is an unaddressed issue in the substantiation of the health claim.  
EFSA assume the health claim targets for those people wishing to lower PPG response. This 
could include individuals at risk of or diagnosed with diabetes. Achieving good glycaemic 
control is an important factor in the management of diabetes (ADA, 2008). As part of this, 
the American Diabetes Association (ADA) recommends that individuals with diabetes aim to 
maintain normal blood glucose levels. As dietary sources of available CHO contribute to rises 
in PPG, it may seem intuitive to reduce the inclusion of these foods. However, the ADA 
discourages the use of low carbohydrate diets (<130 g/d) (ADA, 2008). The ADA guidelines 
for primary and secondary prevention of diabetes encourage the inclusion of low GI 
carbohydrates that are high in fibre (14g/1000kcal) (ADA, 2008).  
The consumption of carbohydrates with a low GI ranking confer a relatively lower glycaemic 
response than of a food ranked high GI (Jenkins et al., 1981). In testing the hypothesis that 
glycaemic response affected glycaemic control, there have been inconsistent findings on 
whether the consumption of lower GI foods compared to high GI foods provides a benefit. 
Despite heterogeneity among the outcomes of intervention trials analysed in two meta-
analyses, overall a modest reduction in HbA1c and fructosamine has been found when 
comparing low and high GI diet interventions (Brand-Miller et al., 2003;Opperman et al., 
2004). These findings were especially significant for those with diabetes compared to 
healthy individuals. However, no benefit of diets differing in GI or GL on HbA1c were found 
in a large (n=162) parallel study in individuals with T2DM conducted over a year (Wolever et 
al., 2008).  
This could be explained by the short study duration (<3 months) of some intervention 




study, a reduction in HbA1c was seen at 3 months but this was temporary and increased 
over the rest of the study duration. An unexpected finding was that lower fasting plasma 
glucose was found following the high GI diet compared with the low GI diet, contrary to the 
hypothesis that low GI foods assist with better glycaemic control. Another explanation for 
the lack of effect of diets differing in GI on HbA1c could relate to the small GI diet difference 
of 8 units. As dietary changes had to be sustained over a year, the difference in diet GI was 
smaller than those used in previous intervention studies which could also explain why a 
possible HbA1c lowering effect of a low GI diet wasn’t seen (Brand et al., 1991;Giacco et al., 
2000). It is also possible that the severity of dysglycaemia is another factor to consider in 
how effective a low GI diet may be compared to a high GI diet. The HbA1c level of 
participants in Wolever et al’s study was lower than those of previous intervention studies 
(Brand et al., 1991;Giacco et al., 2000), possibly making reductions harder to detect.  
However, whether the effect of consuming sugary beverages that partially replace sucrose 
with fructose is tantamount to undertaking a low GI diet similar to those in the previously 
described GI studies is unlikely. GI studies tend to define their low GI component by the 
inclusion of foods such as oats, brown rice and wholegrain bread which make up a 
significant (>50%) proportion of carbohydrate in the diet (Brand-Miller et al., 
2003;Opperman et al., 2004;Wolever et al., 2008;Brand et al., 1991;Giacco et al., 2000). The 
question arises as to how many fructose-replaced foods and beverages one must consume 
to observe any effect on glycaemic outcomes. The inclusion of added fructose is not 
recommended by the ADA in the diets of those with diabetes as fructose has been shown to 
adversely affect plasma lipids (ADA, 2008). The consumption of SSB has generally been 
linked to numerous negative health outcomes, such as weight gain (Malik et al., 
2013;Ebbeling et al., 2006), obesity (Hu, 2013) and hypertension and CVD  (Xi et al., 2015). 
Indeed, the inclusion of added fructose in the diet has been implicated as an independent 
risk factor in the development of T2DM (DiNicolantonio et al., 2015).  
While a reduced PPG response is recommended in the management of diabetes, the ADA 
also considers the use of GI to confer a modest benefit when considering carbohydrate 
intake in isolation, and recommends that those with diabetes follow a dietary pattern that 
includes carbohydrate and dietary fibre from fruit and vegetables, low fat milk, whole grains 




advice in line with national dietary recommendations but not all low GI foods conform to 
healthy guidelines. Indeed, while commercially available convenience foods such as 
processed breakfast cereals, spreads and muesli bars can be formulated to be low GI, they 
can be energy-dense through sugar and fat content, questioning whether the dietary 
inclusion of all foods that are marketed as promoting a lower PPG response is necessarily 
beneficial (Chiu et al., 2011).  
In addition to individuals with diabetes, those with normal glucose tolerance could be 
attracted by health claims. The proposed wording of EFSA’s health claim details how there is 
“no rapid drop in blood sugar, energy is released into the body slowly and prevents feelings 
of tiredness due to the sugar peek (sic) drop”. The wording of the claim can pique the 
interest of individuals with normal glucose tolerance as it can be assumed that feelings of 
tiredness are usually perceived as negative. Indeed, a consumer research group found that 
GI was associated with positive perceptions of energy (Mitchell, 2008).Hence, there is 
evidence that those with normal glucose tolerance could be influenced by claims around 
blood glucose management. This has potential for benefit as post-prandial hyperglycaemia 
has been linked as a risk factor for the development of CVD (Ceriello, 2000;Inoue and Node, 
2009;Ratner, 2001).  
The modest benefit found from low GI interventions (Brand-Miller et al., 2003;Opperman et 
al., 2004) results from an reduction in GI of the overall diet, as opposed to isolated 
consumption of SSB and sugary foods. To base diet GI reduction around the consumption of 
fructose has serious risks that come with fructose overconsumption (Stanhope et al., 
2009;Bray, 2010;Lustig et al., 2012;Hu, 2013). Thus, the health claim should be put in 
context of choosing sugary food products replaced with fructose alongside the consumption 
of a lower overall diet GI if improvement in glycaemic control is desired.  
5.2 Uric Acid Response 
 
While EFSA have based a health claim on the effect of partial fructose substitution on 
glycaemic response, the effect of fructose on changes to uricemia was not discussed. In this 
study, plasma UA concentration rose significantly relative to the sucrose control for all 




permissible if 30% replacement with fructose, it is relevant to examine the UA response to 
the 33% fructose replacement on an individual level in comparison to sucrose. There was 
variability in the type and magnitude of individual responses after consuming the 33% 
fructose replacement drink; while two participants initially had small decreases in UA, other 
participants experienced much larger rises, with one participant’s urate levels increasing by 
101 µmol/L. 
 It is unclear whether this effect can be categorically labelled harmful or beneficial. UA has 
an antioxidant role in plasma, protecting cells from oxidative damage (Sautin and Johnson, 
2008). However, chronic high levels of circulating UA, hyperuricemia, are a risk factor for 
gout. For those at risk of gout or suffering from gout, the Arthritis Foundation has 
recommended that sugary beverages, presumably because of the fructose component, be 
avoided. This recommendation echoes the NZ Ministry of Health advice to reduce intake of 
sugary drinks and orange juice for lowering UA and preventing incidence of gout (MOH, 
2015). A 2012 systematic review conducted by the American College of Rheumatology has 
advised patients with gout to limit consumption of fructose-rich foods and drinks in the 
management of gout (Khanna et al., 2012).  
However, while urate overproduction is a contributing factor, the bulk of the cause of 
chronic hyperuricemia is due to under excretion of urate (Choi et al., 2005;MacFarlane and 
Kim, 2014). Thus, those with compromised renal excretion of urate would benefit from 
lowering intake of foods that increase circulating UA. For people with normal renal 
excretion, a small increase in fructose consumption from partial sucrose replacement in 
sugary beverages is unlikely to be problematic. At an individual level, the urate levels of one 
participant increased by 101 µmol following consumption of the 33% fructose replacement 
beverage. This is a relatively large increase in UA which is at odds with nutrition guidelines 
for those with gout to aim to reduce serum urate levels (Choi et al., 2005;MacFarlane and 
Kim, 2014).  This raises the question as to whether increasing fructose concentration in food 
items should come with a health warning for those with gout. Interestingly, an assessment 
of the variability of individual susceptibility is a priority topic for EFSA future health claims 





5.3 Blood Pressure Response 
 
The primary evidence for fructose-induced hypertension came from animal studies, in which 
mice and dogs consumed fructose at high levels, e.g. fructose comprised 60% of their diet. 
After feeding for 28 days (dogs) and 12 weeks (mice), increases in BP were found, which 
provided an early model for exploring fructose as a causative factor for hypertension in 
humans (Martinez et al., 1994;Singh et al., 2008).  
UA has also been associated as a risk factor to hypertension. A mechanism for fructose-
induced hypertension was thought to arise by uric-acid mediated endothelial dysfunction 
(Feig, 2012;Ha et al., 2012;Jayalath et al., 2014;Klein and Kiat, 2015). Hyperuricemia is 
believed to contribute to hypertension by reducing levels of vasodilators such nitric oxide 
and eNOS (endothelial nitric oxide synthase) (Klein and Kiat, 2015). UA has also been shown 
to induce the expression of C-reactive protein in a dose-dependent manner (Kang et al., 
2005).     
In this study, there were no significant differences in BP observed between the sucrose 
control and the other treatments, except for a significant decrease seen for SBP between 
the 67% fructose replacement and the sucrose replacement. While this finding is of interest, 
it warrants further testing in studies with a larger sample size to conclude if fructose 
decreases BP in acute settings, especially as a previous study found BP to increase following 
ingestion of 60 grams of fructose (Brown et al., 2008)   
However, these findings are unsurprising as they are consistent with large observational 
studies that report no significant relationship between fructose and chronic increased BP 
(Forman et al., 2009;Jalal et al., 2010). Additionally, a meta-analysis of 15 intervention trials 
concluded that there was a possibility that fructose may instead lower DBP and MAP when 
comparing feeding trials that tested fructose against other sources of carbohydrate, 
including glucose, starch, HFCS and sucrose (Ha et al., 2012).  
5.4 Chronic Disease 




EFSA have acknowledged that high levels of fructose (≥25% total energy) consumption have 
been associated with negative health outcomes, such as increased visceral adiposity, insulin 
resistance and dyslipidemia (Agostoni C, 2011). The negative health outcomes that arise 
from fructose overconsumption have been well-documented in feeding studies (Stanhope 
et al., 2009;Lustig et al., 2012). An intervention study that compared the effect of glucose 
and fructose in hypercaloric doses found increased visceral adiposity and deteriorative 
alterations in markers of lipid metabolism during fructose but not glucose consumption 
(Stanhope et al., 2009). Another feeding study in which healthy participants either 
consumed 150 grams of fructose or glucose daily found an elevation in plasma TAG in only 
the fructose intervention group (Silbernagel et al., 2011).  
It is important to put into context the dose of fructose that is required to observe these 
effects. A meta-analysis of 51 isocaloric and 8 hypercaloric feeding trials in which fructose 
was exchanged for other carbohydrates found that fructose did not have any effect on lipids 
at doses of 60-150g/d (Chiavaroli et al., 2015). However hypercaloric trials found 
triglycerides and Apolipoprotein B to increase after fructose was administered at doses of 
163-213 g/d. Another meta-analysis of 14 isocaloric trials and 2 hypercaloric trials found 
triglycerides to increase only in hypercaloric trials in which the median fructose dose was 
175 g/d (Wang et al., 2014).  
In this study, the effect of fructose replacement on lipid profiles was not investigated. 
However, a 33% fructose replacement only increases total fructose content by 16.5 grams in 
a 1 litre beverage of 10% sugar concentration. This is a relatively small increase in fructose 
consumption for those exposed to fructose through SSB. Thus, it seems unlikely that a 
marginally small amount of fructose would contribute significantly to increased 
triglycerides; however this would need to be ascertained in a clinical trial.  
5.5 Strengths and Limitation 
 
This study has a novel approach in that it is the first to test the effects of a partial 
replacement of sucrose with fructose.  Studies have compared fructose and sucrose against 
each other but never as a blend of both sugars. This approach is increasingly relevant as it 




33% replacement but also 50% and 67%, allows comparison of response across fructose 
concentration levels and ascertains the level of fructose concentration required to elicit a 
significantly lower glycaemic response. 
The crossover design of this trial minimises confounding covariates such as intra-individual 
variation and allows participants to act as their own control, allowing for sturdier 
comparison of each treatments’ effect. Procedures were standardised and carried out in a 
clinical laboratory with the assistance of trained personnel. The sucrose control treatment 
was tested twice in order to provide a stable comparative standard.  
A limitation of this study is the sample size of 12. Although it was adequately powered to 
detect a difference of 30% in postprandial iAUC, i tis conceivable that differences smaller 
than this could be useful, for which the study would have been underpowered. However, 
the sample size was in accordance with GI testing for a sample of 10 or more participants is 
recommended (Brouns et al., 2005;AustralianStandard, 2007).  
The results of this study are limited to an assessment of the acute effects of partial 
replacement of sucrose with fructose but the chronic, long term effect of the partial 
replacement remains unknown.  
Our study sample was a small convenience sample; hence the data may not be generalizable 
to the general NZ population.  This sample comprised of healthy participants, therefore the 
findings of this study may not be generalizable to participants with compromised glucose 










6 Conclusions, Recommendations and Direction for Future Research 
 
There was no statistically significant difference in glycaemic response between sucrose and 
33% fructose replacement under our experimental conditions. We were underpowered to 
detect a difference of 20% in glycaemia of but it could be argued that this level of difference 
is marginal. While the ADA recommends that those with diabetes aim to maintain their 
blood glucose levels to as normal as possible, this is a recommendation that isn’t based on 
consistent evidence from clinical trials. Indeed, whether an attenuated post prandial 
glycaemic response necessarily contributes to improved glycaemic control has not been 
consistently demonstrated, as exemplified by trials that compare low and high GI diets 
(Wolever et al., 2008;Brand et al., 1991;Giacco et al., 2000).     
Further, the health claim targets those wanting to reduce their PPG response. For those 
with diabetes, added fructose intake has been discouraged by the ADA due its effect on 
plasma lipids at high levels of intake. Therein lays an inherent inappropriate aspect to a 
health claim that seeks to target those vulnerable to impaired glucose metabolism. In this 
study, UA increased substantially and significantly with 33% fructose replacement, 
prompting concern for those with compromised UA metabolism and gout management.  
These findings question whether it is fitting to put a health claim on sugary food and drink 
containing added fructose, and in a broader sense, whether it is appropriate to permit the 
use of health claims on sugary foods as this impresses to the average consumer a condoning 
of sugar consumption. SSB’s provide an exposure to excess energy and fructose; studies 
consistently show an association between SSB and weight gain, as well as metabolic 
abnormalities such as hyperuricemia (Malik et al., 2013;Lin et al., 2012;Nguyen et al., 
2009;NZBGP, 2014). In light of these findings, the NZ Beverage Panel have released 
recommendations for industry to promote sugar-free beverages as a preferred option over 
SSB (NZBGP, 2014).    
 Health claims should serve to communicate a clear health benefit of a nutrient or food to 
consumers, and should be worded unambiguously so that the message being marketed 
cannot be misconstrued by the consumer (Marinangeli and Harding, 2016). Whether the 




temporary attenuation in PPG can thus be questioned. This is at odds with EFSA’s terms of 
reference relating to health claims, which states that health claims should be well 
understood by consumers. Furthemore, health claims permissible by EFSA are required to 
demonstrate significant beneficial effects; EFSA states that that scientific evidence about the 
role of a nutrient alone is inadequate justification for the basis of a health claim. In light of 
these conditions created by EFSA, the substantiation of health claim ID 558 seems 
contradictory.  
It may be more appropriate then that sugary foods and beverages should not bear any 
health claims whether or not sucrose or glucose has been partially replaced with fructose. 
Although a modest reduction in PPG might be achieved, the wider implications of 
consuming sugary foods and beverages, including excess energy intake contributing to 
obesity (DiNicolantonio et al., 2015;Hu, 2013) and the issue of fructose and uricemia need 
to be considered (Choi et al., 2005;Rho et al., 2011).   
If thought to be worthwhile, future research in this area could expand to investigating the 
chronic effect of partial fructose-substituted foods and beverages on long term glycaemic 
control and lipid metabolism. While testing the acute response of the health claim provides 
information of interest, testing of the health claim on chronic health is of utmost 
importance to understand how increasing fructose consumption will affect consumers.   
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sugar-sweetened beverages advised by organisations including Diabetes New Zealand as 
these beverages are a source of unnecessary calories. Although the claim may look 
attractive, in practice the consumption of any added sugar beverage by people with type 
2 diabetes is discouraged. 
Nevertheless, the health claim has been allowed and it applies when there is only a 
minimum replacement of 33% fructose. Whether there is a blood glucose reduction at 
this level of replacement has not been tested. Additionally, fructose has the potential to 
acutely raise blood pressure and plasma uric acid, which would be regarded as 
undesirable effects. Hence the aim of this work is to test the glycaemic, uricaemic and 
blood pressure raising potential of sweetened beverages containing sucrose and fructose 
added in various proportions to test beverages. To achieve this we propose to recruit 
volunteers who are willing to drink beverages containing 10.8% by volume of sugar 
(10.8% is the amount of sugar commonly present in commercially-available drinks). The 
volunteers would test four drinks as follows: 1. One-third fructose and two-thirds sucrose 




alone (tested twice and used as the reference drink). Following consumption, six further 
blood pressure readings would be taken and six venous blood samples collected at 
regular intervals over a two-hour period from which a time course of blood pressure, 
blood glucose and plasma uric acid concentrations would be determined. A questionnaire 
will be given to the participants asking them to rate their drink preference.  
Another aspect of this research is to assess hedonic preference to various sugar blends 
using proprietary software (Compusense® five). On five occasions (one training session 
and four data collection sessions), participants will taste sugary beverages with an overall 
consumption less than 75 ml whilst interacting with the software via keyboard, in order 
to provide a hedonic judgement and to record the temporal sweetness profile for the 
sample. The sensory test will take half an hour and will follow immediately after the two-
hour blood collection procedure such that the total amount of time to complete the 
blood collection and the sensory components will be two and a half hours. 
EFSA. European Food Safety Authority. Scientific Opinion on the substantiation of health 
claims related to fructose and reduction of post-prandial glycaemic responses (ID558) 
pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2223 
 
12.        Researcher/instructor experience and qualifications in this research area  
Dr. Venn is experienced in conducting research trials involving human participants. 
Testing will be carried out according to our standard procedure in the Department 
of Human Nutrition Undergraduate Laboratories.  
 
13. Participants   
13(a) Population from which participants are drawn: General Dunedin population  
13(b) Inclusion and exclusion criteria:  
Inclusion: men and women in the age range of 18 – 60 y, inclusive. 
Exclusion: Women who are pregnant, people with diabetes mellitus, people taking 
medicine that affects glucose absorption and metabolism, and people who malabsorb 
fructose. Fructose malabsorption is not a serious condition and may cause flatulence and 






13(c) Estimated number of participants: 15  
13(d) Age range of participants: 18-60y 
13(e) Method of recruitment: Recruitment will be conducted by posting flyers 
advertising the details of our trial around the University of Otago. 
13(f) Specify and justify any payment or reward to be offered  
$100 reimbursement per participant 
14. Methods and Procedures:  
The blood collection for uric acid and glucose, and the blood pressure measurements 
would take place in the Department of Human Nutrition clinic. The sensory study would 
take place in the Department of Food Science.  
Human Nutrition Blood Collection Laboratory 
Volunteers would report to the Human Nutrition laboratory on the morning of each test 
day following an overnight fast. An Information Sheet would have been sent to 
volunteers prior to their first test day. On arrival for the first time, research staff will 
explain the purpose and scope of the laboratory and answer any questions regarding the 
study. If participants are willing to continue, a consent form (attached) will be given to 
them. Participants will have their height and weight measured in a screened-off area to 
ensure the participants privacy. A questionnaire will be administered to ensure that 
eligibility criteria are met and for collection of demographic data. Test beverages will be 
provided to participants. Carbonated water purchased from a supermarket will be 




Participants will attend the laboratory after an overnight fast of at least 10 hours. 
On the evenings preceding each of these test days, participants will be advised not 
to exercise and to ensure that their evening meal contains a carbohydrate-rich 
food.  
 
Blood pressure and blood collection procedure 
Blood pressure will be taken on seven occasions at the following times: at baseline 
and at 15, 30, 45, 60, 90, and 120 minutes after consumption of the test beverage 
in accordance with the Department of Human Nutrition good clinical practice 




three systolic blood pressure readings is greater than 140 mmHg or less than 90 
mmHg, the participant will proceed with the laboratory and will be advised to 
consult his or her healthcare provider. 
 
For measuring blood glucose and serum iric acid, venous blod will be collected by 
the Department of Human Nutrition nurse by placing a 20G cannula into a vein in 
the anterior cubital fossa. The cannula will be a sterile procedure, secured with 
medical tape and immediately flushed with 10mls of normal saline. An 
observation period of 10 minutes will be implemented to ensure the correct 
placement of the cannula.  
 
Drawing of blood will occur at baseline and at 15, 30, 45, 60, 90 and 120 minutes. 
Prior to collectection of the sample, a 0.5ml-1ml draw will be taken and discared 
to allow for dilution. Following each draw, the cannula site will be flushed with 
1ml of sterile normal saline solution.  
 
This method of collection blood for analysis causes minimal discomfort to the 
participant. The total volume of blood extracted for sampling will be 3.5 milliliters, 
with an approximate volume of 3.5-7 millilitres discharged to allow for dilution. 
The insertion of a cannula may cause some discomfort with the possibility of 
inflammation occurring in the vein originating at the insertion site (phlebitis). This 
is unlikely given the sterile procedures followed by our research nurse, but in the 
rare event of this happening, the participant would be withdrawn from the study 
and referred to their general practitioner. 
 
Blood Analysis 
Blood glucose and plasma uric acid concentrations will be determined using 
proprietary test kits on a COBAS Analyzer housed within the Department.  
 
Test drinks 
Each participant will test the reference drink (sucrose) on two occasions and the 
test drinks (blends of fructose:sucrose in the proportions of 0.33:0.67, 0.50:0.50, 
and 0.67:0.33) once each; the total of five tests will be carried out on non-
consecutive days. The total amount of sugars in the beverages will be 50 g, 
consistent with the amount used for glycaemic index testing. 
 
Statistics 
The EFSA health claim is substantiated on fructose having a lower glycaemic index 
than sucrose. The sample size of 15 therefore is in accordance with the minimum 




determination of the glycaemic index. A mixed model with participant as a 
random effect will be used to analyse the data providing estimates of the 
difference in outcome between the reference and test beverages. 
 
Food Science Laboratory 
Following each of the five testing sessions at the Human Nutrition laboratory, participants 
will attend the Food Science laboratory (5-minute walk from the Human Nutrition 
laboratory). Each sensory profile testing will require 30 minutes of time. On the first visit 
to Food Science, participants will be given training on the use of the sensory software 
Compusense® five. The training will involve tasting the reference beverage (sucrose) at a 
range of different concentrations. On the four subsequent visits, participants will perform 
hedonic and sensory profiling tasks on five sugary beverages. The order in which samples 
are tested will be randomized for each session to allow for replicated tests of the 
reference beverage (sucrose) and the test beverages (blends of fructose:sucrose in the 
proportions of 0.33:0.67, 0.50:0.50, and 0.67:0.33). To assess a beverage, participants will 
taste a small volume (15 ml) whilst interacting with Compusense® five via a keyboard to 
record a temporal sweetness profile and to provide a hedonic score. Overall, a participant 
will consume less than 75 ml of solution in each session. Water and other palate cleansers 
(e.g., water crackers) will be provided to the participants throughout the testing. The 
participants will be given options to take breaks from the testing at any point of time. 
15. Compliance with The Privacy Act 1993 and the Health Information Privacy Code 
1994 imposes strict requirements concerning the collection, use and disclosure of 
personal information.  The questions below allow the Committee to assess compliance. 
15(a) Are you collecting and storing personal information (e.g.name, contact details, 
designation, position etc) directly from the individual concerned that could identify the 
individual? (Delete the answer that does not apply.) 
YES  
15(b) Are you collecting information about individuals from another source?  
NO 
If YES, explain: 
 
15(c) Collecting Personal Information (Delete the answer that does not apply): 
• Will you be collecting personal information (e.g. name, contact details, position, 
company, anything that could identify the individual)? 




• Will you inform participants of the purpose for which you are collecting the 
information and the uses you propose to make of it? 
 YES  
• Will you inform participants of who will receive the information? 
 YES  
• Will you inform participants of the consequences, if any, of not supplying the 
information? 
             YES  
• Will you inform participants of their rights of access to and correction of personal 
information? 
 YES  
Where the answer is YES, make sure the information is included in the Information Sheet 
for Participants. 
 If you are NOT informing them of the points above, please explain why: 
 
 
15(d) Outline your data storage, security procedures and length of time data will be 
kept  
The information will remain confidential to the study investigators. Paper copies will be 
kept in a lockable office and electronic data stored on departmental computers in 
password protected files. The results of this study may be published but no individual's 
identity will be revealed. At the end of the project any personal information will be 
destroyed immediately except that, as required by the University's research policy, any 
raw data on which the results of the project depend will be retained in secure storage for 
five years, after which it will be destroyed. 
 
15(e) Who will have access to personal information, under what conditions, and 
subject to what safeguards? If you are obtaining information from another source, 
include details of how this will be accessed and include written permission if 
appropriate.  Will participants have access to the information they have provided? 
Only Dr Bernard Venn will have permanent access to the personal information. Paper 
copies will be stored in Dr Venn's University of Otago office and any information 
transferred into digital form will be stored on Dr Venn's University computer. If a 




university password-protected computer. At the completion of data entry, the student 
will be asked to transfer the electronic file to Dr Bernard Venn and to delete the file from 
the student computer. Statistical analysis undertaken using anonymous data. 
 
15(f) Do you intend to publish any personal information they have provided? 
 NO 
 If YES, specify in what form you intend to do this: 
 
15(g) Do you propose to collect demographic information to describe your sample? 
For example: gender, age, ethnicity, education level, etc. 
Yes 
 
15 (h) Have you, or will you, undertake Māori consultation? Choose one of the options 
below, and delete the option that does not apply: 
 (Refer to http://www.otago.ac.nz/research/maoriconsultation/index.html). 
NO If not, provide a brief outline of your reasons (e.g. the research is being 
undertaken overseas): 
YES  Māori consultation has been undertaken; form submitted 8/05/15.  
 
16. Does the research or teaching project involve any form of deception?   
NO 
 If yes, explain all debriefing procedures: 
 
17. Disclose and discuss any potential problems or ethical considerations: 
The research staff will only work with data corresponding with the study ID as an 
identifier, rather than names.  
There may be some discomfort from placement of venous cannula and blood sampling.  
 
18. *Applicant's Signature:   .............................................................................   
 Name (please print): ………………………………………………………. 




 *The signatory should be the staff member detailed at Question 1. 
 
 
19. Departmental approval:  I have read this application and believe it to be valid 
research and ethically sound.  I approve the research design.  The Research proposed in 
this application is compatible with the University of Otago policies and I give my consent 
for the application to be forwarded to the University of Otago Human Ethics Committee 
with my recommendation that it be approved. 
Signature of **Head of Department: .......................................................................... 
 Name of HOD (please print): ………………………………………………………. 
  Date: ..................................................... 
**Where the Head of Department is also the Applicant, then an appropriate senior staff 



















Appendix B: Maori Consultation Form 
 
Principal Investigator 1 
Name:  Dr Bernard Venn 
Department: Department of Human Nutrition 
Campus: DUNEDIN 
Email: bernard.venn@otago.ac.nz Telephone: Not Supplied 
    03 479 5068 
 
Principal Investigator 2 
Name:  Prof Indrawati Oey 
Department: Food Science 
Campus: Otago 
Email: indrawati.oey@otago.ac.nz Telephone: Not Supplied 
    03 479 8735 
 
Is this Otago District Health Board research? 
No  
Does this research involve human participants? 
Yes  
Description in lay terms of the proposed research 
The purpose of this laboratory is to examine the acute effects post-consumption of 
sweetened beverages formulated with varying proportions of different sweeteners. 
Measured outcomes will be changes in blood glucose, blood pressure, serum uric acid 
concentrations and sensory profiles in response to consuming various carbohydrate 
containing beverages.  
Description in lay terms of the potential outcomes of the area of research  
The European Food Safety Authority allows manufacturers of sugary beverages to make a 
health claim when fructose is used as a sweetener. It may be desirable for Australian and 




food regulatory authority (Food Standards Australia New Zealand) we need to confirm 
that the claim is valid in the Australasian setting and that there are no undesired effects 
from using fructose. 
Potential areas that are of interest to or of concern for Māori 
Diabetes has a high prevalence in the Māori population and features as one of the top 
five causes of death in Māori (MoH, 2010). Fructose elicits a lower post prandial 
glycaemic response relative to sucrose, which forms the basis of the health claim by EFSA 
as good glycaemic control and attenuation of post-prandial glycaemia has been shown to 
be beneficial for the prevention and treatment of type 2 Diabetes Mellitus and 
cardiovascular disease. The prevalence of gout among Māori is one of the highest in the 
world (Te Karu, 2013). Gout is caused by chronic elevation of uric acid in the blood. One 
source of uric acid production is a high intake of the sugar fructose. Table sugar (sucrose) 
comprises half fructose and half glucose therefore fructose can be consumed in large 
amounts when people drink sugary beverages. Our intention is to ask the participants to 
consume sweetened beverages in varying proportions of fructose and sucrose to measure 
the change in serum uric acid. 
Collaborations in this area of research  
Potential funding bodies 
University funded  
Location 
University of Otago human nutrition undergraduate laboratory  
Other relevant information 
References 
Ministry of Health. 2010. Tatau Kahukura. Māori health chart book 2010. 2nd Edition. 
Wellington: Ministry of Health) 
Te Karu et al. Māori experiences and perceptions of gout and its treatment: a kaupapa 






Appendix C: Study Information Sheet  
 
Testing of a health claim; the glycaemic lowering potential and sensory profile of 
partial replacement of sucrose with fructose in a carbonated beverage. 
 
INFORMATION SHEET FOR PARTICIPANTS  
Thank you for showing an interest in this project. Please read this information sheet 
carefully before deciding whether or not to participate. If you decide to participate we 
thank you. If you decide not to take part there will be no disadvantage to you and we 
thank you for considering our request.  
What is the Aim of the Project?  
The aim of this study is to test the glycaemic properties and uric acid raising potential of 
beverages sweetened with sucrose and fructose in various proportions. This requires 
attending the laboratory on five occasions.   
What Type of Participants are being sought?  
Healthy men and women between the ages of 18 – 60 y. Exclusion criteria are women 
who are pregnant, people with diabetes mellitus, people who malabsorb fructose, and 
taking medicine that affects glucose absorption and metabolism. 
What will Participants be asked to do?  
Main laboratory experiment 
 
You will be asked to attend the Department of Human Nutrition Laboratory on five 
occasions (non-consecutive days), as you will be testing beverages with varying 
proportions of different sweeteners. If eligibility criteria are met, you will be asked to 
read and sign a consent form, we will collect some personal information from you 
comprising demographics, height and weight. Following this, the first test will be 
conducted. Testing is conducted in the morning with a start time of between 7 -8 am. You 
will be required to fast, ie: to have no food, no sugar-sweetened chewing gum or drinks 
except water after 10 pm on the night before the test. We would prefer that you did not 
walk to the University. If you do walk or cycle we would like you to arrive 20 minutes 
early so that your heart rate and blood glucose have a chance to settle down before you 
start the test. On arrival your blood pressure will be taken following which a cannula will 
inserted into a vein in the anterior cubital fossa from which blood samples will be taken in 
the fasting state. You will then be given a test beverage to consume. After this, additional 
blood pressure readings and blood samples will be taken at 15, 30, 45, 60, 90 and 120 
minutes. The insertion of a cannula may cause some discomfort with the possibility of 




unlikely given the sterile procedures followed by our research nurse, but in the rare event 
of this happening, you would be withdrawn from the study and referred to your 
general practitioner. The total volume of blood collected will amount to 3.5 millilitres. 
During the two hours we would like you to remain seated in the room with the exception 
of toilet visits if necessary. You are free to read or talk. At the end of the two hours we 
would like you to walk over to the Food Science building (5 min walk). On the first visit to 
Food Science you will be trained in the use of a simple computer task aimed to assess 
your taste experience of the beverage; on the four subsequent visits you will be given 
small volumes (less than a quarter of a cup) of other sugary beverages sweetened with 
various proportions of sucrose and fructose. Testing at Food Science will take half an hour 
on each occasion. On completion there will be some food for you to eat on the premises 
or to take away.  
 
What Data or Information will be Collected and What Use will be Made of it?  
For the main laboratory exercise we will collect data on your age, ethnicity, smoking 
habits and gender and we will be measuring your height and weight. The purpose of 
collecting this information is to describe the overall characteristics of the study 
population. We will also ask you to fill in a questionnaire to ensure you meet the study 
eligibility criteria. From your blood samples we will be testing glucose and uric acid 
concentration. The information will remain confidential to the study investigators. Paper 
copies will be kept in a lockable office and electronic data stored on a departmental 
computer. The results of the project will be pooled and may be published and available in 
the University of Otago Library (Dunedin, New Zealand) but every attempt will be made 
to preserve your anonymity. The data and samples collected will be securely stored in 
such a way that only those mentioned below will be able to gain access to it. Data and 
samples obtained as a result of the research will be retained for at least 5 years in secure 
storage. Any personal information held on the participants such as contact details may be 
destroyed at the completion of the research even though the data and samples derived 
from the research will, in most cases, be kept for much longer or possibly indefinitely. If 
you choose not to supply information this may exclude you from taking part in the study. 
You have rights of access to the personal information that you have given to us and you 
may correct or change this information.  
Testing blood glucose has the potential to reveal whether a person has diabetes or is at 
risk of pre-diabetes. If elevated blood glucose concentrations are found, you will be 
advised to make an appointment with student health or with your general practitioner. If 
the average of three systolic blood pressure readings is less than 90 or greater than 140 
mmHg, you will be able to proceed with the laboratory but we will advise you to consult 




Can Participants Change their Mind and Withdraw from the Project?  
You may withdraw from participation in the project at any time and without any 
disadvantage to yourself.  
What if Participants have any Questions?  
If you have any questions about our project, either now or in the future, please contact - 
Dr Bernard Venn; Department of Human Nutrition 
Telephone: 03 479 5068 email bernard.venn@otago.ac.nz 
This study has been approved by the University of Otago Human Ethics Committee. If you 
have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (ph 03 479 8256). Any 






















Appendix D: Consent Form 
 
Testing of a health claim; the glycaemic lowering potential and sensory profile of 
partial replacement of sucrose with fructose in a carbonated beverage. 
   
CONSENT FORM FOR PARTICIPANTS 
 
I have read the Information Sheet and understand the procedures. All my questions have 
been answered to my satisfaction. I understand that I am free to request further 
information at any stage.  
I know that: 
1. My participation in the project is entirely voluntary;  
2. I am free to withdraw from the project at any time without any disadvantage to 
myself  
3. Personal identifying information will be destroyed at the conclusion of the project 
but any raw data on which the results of the project depend will be retained in 
secure storage for at least five years;  
4. Cannula insertion may cause some discomfort with the possibility of local 
inflammation. 
5. The results of the project may be published and will be available in the University 
of Otago Library (Dunedin, New Zealand), but every attempt will be made to 
preserve my anonymity 
 
I consent to attending the laboratory on five days following an overnight fast, 
consuming the study beverage, having blood pressure taken and providing seven 
venous blood samples obtained by venous blood sampling over two hours on each 
test day.  
 
 




Name ..............................................................................  
Signature................................................ 
 Date ........................ 
This study has been approved by the University of Otago Human Ethics Committee. If you 
have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (ph 03 479 8256). Any 





Appendix E: Participant Demographic Questionnaire 
 
Personal information questionnaire   ID No: 
 
1. Age: 
2. Sex:  M F 
3. Height (cm): 
4. Weight (kg): 
5. Do you smoke cigarettes? 
Yes 
No   
 
 
6. Which ethnic group do you belong to? Tick the options that apply to you. 
 
o NZ European 
o Māori 
o Pacific Islander 
o Chinese 
o Indian 
o Other please specify 
 
7. Please confirm that you are  
 
o Not pregnant 
o Not been diagnosed with diabetes 







Appendix F: Blood Pressure Recording Sheet 
 











Blood pressure at 
baseline: 
 




     
Blood pressure at 
15 min: 
 




     
Blood pressure at 
30 min: 
 




     
Blood pressure at 
45 min: 
 




     
Blood pressure at 
60 min: 
 




     
Blood pressure at 
90 min: 
 
Time of collection: 
Additional 





Blood pressure at 
120 min: 
 
Time of collection: 
Additional 
comments 
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